RRM1在非小细胞肺癌的表达与吉西他滨耐药性的研究进展

RRM1 in non-small cell lung canaer with gemcitabine resistance research

肺癌是目前全球范围内发病率和病死率最高的恶性肿瘤，其中约有80％为非小细胞肺癌，第3代化疗药物吉西他滨、紫杉醇、多西紫杉醇、长春瑞滨等的出现和应用，肺癌的治疗无进展期和中位生存期有所提高，但远未达到我们所期望的目标，癌细胞出现耐药性是影响疗效的主要因素。核苷酸还原酶M1是被关注的抑癌基因，它与吉西他滨的耐药性的关系引起广泛的关注，在此就其相关性作一综述。

Lung cancer has the highest morbidity and mortality in malignant tumors over the world, in which about 80% is non-small cell lung cancer. The emergence and application of the third- gengration chemotherapy drug, gemcitabine, paclitaxe, docetaxe, vinorelbine, etc, result in an increase in lung cancer progression-free survival and median survival, whereas far away from reaching the goal of our expectations. The emergence of drug-resistance in cancer cells is a major factor affecting the efficacy. Ribonucleotide reductase M1 is the cancer suppressor gene which has been concernedlits relationship with gemcitabine resistance has aroused wide public concern. In this paper is the summarization of the relevance.